FBLG SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 30, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Mar 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 24, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 31, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2025

News

TYPE

HEADLINE

FILED AT

8-K

FibroBiologics Enters into Securities Purchase Agreement and Issues Convertible Debenture

Oct 8, 2026

8-K

FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer

Sep 18, 2026

8-K

FibroBiologics Announces Private Placement of Common Stock and Warrants to Chief Scientific Officer

Sep 15, 2026

8-K

FibroBiologics Appoints Legendary Sports Agent Leigh Steinberg to Board of Directors

Aug 24, 2026

8-K

FibroBiologics Receives Nasdaq Delisting Notice Due to Bid Price Deficiency

Jul 24, 2026

8-K

FibroBiologics Appoints Former NASA Astronaut and Microbiologist Dr. Kathleen Rubins to Board of Directors

Jul 9, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

POS AM

SHARE RESALE REGISTRATION | Shares: 41,489,581 EFFECTIVE, DATED 2026-10-19

Oct 13, 2026

POS AM

SHARE RESALE REGISTRATION | Shares: 16,022,644 EFFECTIVE, DATED 2026-10-19

Oct 13, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Oct 13, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Sep 15, 2026

S-3

SHARE RESALE REGISTRATION

Jul 9, 2026

Form D - Notice of Exempt Offering of Securities - Item 06b

Jun 29, 2026

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Sep 9, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 31, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Jul 17, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 5, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

May 5, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 22, 2026

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13D

Khoja Hamid (Filed by)

Sep 17, 2026

Khoja Hamid (Reporting)

Sep 15, 2026

Steinberg Leigh (Reporting)

Sep 1, 2026

SCHEDULE 13G

ARMISTICE CAPITAL, LLC (Filed by)

Aug 14, 2026

Rubins Kathleen Hallisey (Reporting)

Jul 16, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Jul 9, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 20, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 20, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 17, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 1, 2026

CORRESP

Form CORRESP - Correspondence

Mar 27, 2026

CORRESP

Form CORRESP - Correspondence

Mar 27, 2026

FibroBiologics, Inc. Common Stock FBLG · SEC Filings